Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in inoperable CTEPH (China)
CTR20131717Phase 3Suspended
- Sponsor
- GSK
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambrisentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by GSK. Started Jan 2017; status: suspended.
02
Drugs
ambrisentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on CTR20131717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131717.